# AVASTIN® (bevacizumab) - Comprehensive FDA Prescribing Information (2022 Update)

**Source**: Complete FDA Prescribing Information from Mixtral Database  
**Initial U.S. Approval**: 2004  
**Recent Major Changes**: September 2022  
**Updated Sections**: Indications and Usage (1.1), Dosage and Administration (2.2), Warnings and Precautions, Infusion-Related Reactions (5.9)  
**Extracted**: September 2024

---

## INDICATIONS AND USAGE

### Recurrent Glioblastoma (GBM)
- **Patient Population**: Adults
- **Evidence Basis**: FDA approval based on clinical trials
- **Status**: Regular approval (2017)

---

## DOSAGE AND ADMINISTRATION

### Recurrent Glioblastoma
- **Dose**: 10 mg/kg every 2 weeks
- **Route**: Intravenous infusion
- **Duration**: Until disease progression or unacceptable toxicity

### General Surgery Instructions
- **Pre-surgery**: Withhold Avastin for **at least 28 days** prior to elective surgery
- **Post-surgery**: Do not administer for **28 days** following major surgery and until adequate wound healing

---

## COMPREHENSIVE DOSAGE MODIFICATIONS FOR ADVERSE REACTIONS

### Gastrointestinal Perforations and Fistulae
**Severity Requiring Discontinuation:**
- Gastrointestinal perforation (any grade)
- Tracheoesophageal fistula (any grade)
- Fistula (Grade 4)
- Fistula formation involving any internal organ

**Action:** **Discontinue Avastin permanently**

### Wound Healing Complications
**Management:**
- **Any wound healing complication**: Withhold Avastin until adequate wound healing
- **Necrotizing fasciitis**: **Discontinue Avastin permanently**

### Hemorrhage
**Severity-Based Actions:**
- **Grade 3 or 4 hemorrhage**: **Discontinue Avastin permanently**
- **Recent hemoptysis ≥1/2 teaspoon (2.5 mL)**: **Withhold Avastin**

### Thromboembolic Events
**Arterial Thromboembolism:**
- **Severe arterial thromboembolism**: **Discontinue Avastin permanently**

**Venous Thromboembolism:**
- **Grade 4 VTE (including pulmonary embolism)**: **Discontinue Avastin permanently**

### Hypertension
**Management Protocol:**
- **Hypertensive crisis**: **Discontinue Avastin permanently**
- **Hypertensive encephalopathy**: **Discontinue Avastin permanently**
- **Severe hypertension**: Withhold Avastin if not controlled with medical management; resume once controlled

### Posterior Reversible Encephalopathy Syndrome (PRES)
- **Any PRES**: **Discontinue Avastin permanently**

### Renal Injury and Proteinuria
**Monitoring and Management:**
- **Nephrotic syndrome**: **Discontinue Avastin permanently**
- **Proteinuria ≥2 grams per 24 hours**: Withhold Avastin until proteinuria <2 grams per 24 hours

### Infusion-Related Reactions
**Severity-Based Management:**
- **Severe reactions**: **Discontinue Avastin permanently**
- **Clinically significant reactions**: Interrupt infusion; resume at decreased rate after symptoms resolve
- **Mild, clinically insignificant**: Decrease infusion rate

### Congestive Heart Failure
- **Any CHF**: **Discontinue Avastin permanently**

---

## WARNINGS AND PRECAUTIONS WITH INCIDENCE RATES

### Gastrointestinal Perforations and Fistulae
- **Incidence**: **0.3% to 3%** across clinical studies
- **Fatality**: Sometimes fatal
- **Risk factors**: Prior pelvic radiation increases risk
- **Timing**: Majority occur within 50 days of first dose

### Surgery and Wound Healing Complications
- **Incidence in mCRC**: **15%** in patients receiving Avastin vs **4%** without Avastin
- **GBM patients**: **5%** with Avastin vs **0.7%** without
- **Critical timing**: 28-day pre/post-surgery requirement

### Hemorrhage
- **Grades 3-5 hemorrhagic events**: **0.4% to 7%** in patients receiving Avastin
- **Pattern**: Two types - minor (Grade 1 epistaxis) and serious/fatal
- **Risk increase**: Up to **5-fold higher** with Avastin
- **CNS hemorrhage in GBM**: **2.5%** Grade ≥3

### Arterial Thromboembolic Events (ATE)
- **Grades 3-5 ATE**: **5%** with Avastin + chemotherapy vs **≤2%** chemotherapy alone
- **Highest risk**: **GBM patients** have elevated ATE risk
- **Events include**: Stroke, MI, angina
- **Risk factors**: History of ATE, diabetes, age >65

### Venous Thromboembolic Events (VTE)
- **Grades 3-4 VTE**: **11%** with Avastin + chemotherapy vs **5%** chemotherapy alone (Study GOG-0240)
- **Includes**: Pulmonary embolism, deep vein thrombosis

### Hypertension
- **Grades 3-4 hypertension**: **5% to 18%** in patients receiving Avastin
- **Monitoring**: Blood pressure every 2-3 weeks during treatment
- **Management**: Medical management required

### Posterior Reversible Encephalopathy Syndrome (PRES)
- **Incidence**: **<0.5%** of patients across clinical studies
- **Onset**: 16 hours to 1 year after first dose
- **Symptoms**: Headache, seizure, lethargy, confusion, blindness, visual and neurologic disturbances
- **Diagnosis**: MRI confirmation needed

### Renal Injury and Proteinuria
- **Grade 3-4 proteinuria**: **0.7% to 7%** in clinical studies
- **Monitoring**: Dipstick urinalysis for proteinuria
- **Median onset**: 5.6 months
- **Resolution**: Did not resolve in 40% of patients

### Infusion-Related Reactions
- **Severe reactions**: **0.4%** of patients
- **First dose reactions**: **<3%** of patients
- **Symptoms**: Hypertension, wheezing, hypersensitivity

### Embryo-Fetal Toxicity
- **Risk**: May cause fetal harm
- **Animal studies**: Congenital malformations in rabbits at clinical doses
- **Contraception**: Required during treatment and 6 months after

### Ovarian Failure
- **Incidence**: **34%** in premenopausal women receiving Avastin + chemotherapy vs **2%** with chemotherapy alone
- **Impact**: May impair fertility

### Congestive Heart Failure
- **Grade ≥3 left ventricular dysfunction**: **1%** with Avastin vs **0.6%** chemotherapy alone
- **Contraindication**: Not indicated with anthracycline-based chemotherapy

---

## ADVERSE REACTIONS

### Most Common (>10% incidence)
1. Epistaxis
2. Headache
3. Hypertension
4. Rhinitis
5. Proteinuria
6. Taste alteration
7. Dry skin
8. Hemorrhage
9. Lacrimation disorder
10. Back pain
11. Exfoliative dermatitis

### Detailed Adverse Reactions by Cancer Type

#### Non-Squamous Non-Small Cell Lung Cancer
- **Neutropenia**: 27% (Avastin) vs 17% (placebo)
- **Fatigue**: 16% vs 13%
- **Hypertension**: 8% vs 0.7%
- **Infection without neutropenia**: 7% vs 3%
- **Venous thromboembolism**: 5% vs 3%
- **Febrile neutropenia**: 5% vs 2%
- **Pneumonitis/pulmonary infiltrates**: 5% vs 3%
- **Proteinuria**: 3% vs 0%

### Postmarketing Experience (Rare but Serious)
1. **Polyserositis**
2. **Pulmonary hypertension**
3. **Gastrointestinal ulcer**
4. **Intestinal necrosis**
5. **Anastomotic ulceration**
6. **Pancytopenia**
7. **Gallbladder perforation**
8. **Osteonecrosis of the jaw**
9. **Renal thrombotic microangiopathy**
10. **Nasal septum perforation**
11. **Arterial aneurysms, dissections, and rupture** (including aortic)

---

## CLINICAL PHARMACOLOGY

### Mechanism of Action
**Bevacizumab binds VEGF and prevents its interaction with receptors Flt-1 and KDR on endothelial cells, reducing microvascular growth and inhibiting metastatic disease progression.**

### Pharmacokinetics
- **Central volume of distribution**: 2.9 L (22% CV)
- **Clearance**: 0.23 L/day (33% CV)
- **Half-life**: **20 days** (range: 11-50 days)

### Population-Specific Pharmacokinetics
- **Body weight**: Clearance varies by body weight
- **Sex differences**:
  - Males: Higher clearance (0.26 L/day), larger volume (3.2 L)
  - Females: Lower clearance (0.21 L/day), smaller volume (2.7 L)
- **Tumor burden**: Higher tumor burden = higher clearance (0.25 vs 0.20 L/day)

---

## USE IN SPECIFIC POPULATIONS

### Pediatric Use
- **Safety and effectiveness**: Not established in pediatric patients
- **Osteonecrosis risk**: Cases of non-mandibular osteonecrosis observed in patients <18 years

### Geriatric Use
- **Arterial thromboembolic events**: Increased incidence in patients ≥65 years
  - **≥65 years**: 8% incidence
  - **<65 years**: 3% incidence

### Pregnancy and Lactation
- **Pregnancy**: May cause fetal harm
- **Contraception**: Required during treatment and 6 months after last dose
- **Breastfeeding**: Advise not to breastfeed during treatment and 6 months after

### Fertility
- **Females**: Avastin increases risk of ovarian failure and may impair fertility
- **Males**: Effects on male fertility unknown

---

## DOSAGE FORMS AND STRENGTHS

### Single-Dose Vials
- **100 mg/4 mL** (25 mg/mL)
- **400 mg/16 mL** (25 mg/mL)

### Administration
- **First infusion**: 90 minutes
- **Second infusion**: 60 minutes (if first tolerated)
- **Subsequent infusions**: 30 minutes (if second tolerated)

---

## CONTRAINDICATIONS
**None** - No absolute contraindications listed

---

## MONITORING REQUIREMENTS FOR GBM PATIENTS

### Essential Monitoring
1. **Blood pressure**: Every 2-3 weeks during treatment
2. **Proteinuria**: Dipstick urinalysis regularly
3. **CNS hemorrhage**: Monitor for neurologic symptoms
4. **Wound healing**: Assess before any surgical procedures
5. **Arterial thromboembolic events**: Monitor for stroke, MI signs
6. **Infusion reactions**: Monitor during and after infusions

### Laboratory Monitoring
- **Complete blood count**: Regular monitoring
- **Liver function tests**: If indicated
- **24-hour urine protein**: If proteinuria ≥2+ on dipstick

---

## PATIENT COUNSELING POINTS

1. **Surgery timing**: Report any planned surgeries - 28-day hold required
2. **Bleeding risk**: Report unusual bleeding, nosebleeds, headaches
3. **Blood pressure**: Monitor at home if possible
4. **Neurologic symptoms**: Report severe headaches, confusion, vision changes
5. **Wound healing**: Report slow-healing wounds or infections
6. **Pregnancy**: Use effective contraception; may harm fetus
7. **Fertility**: May affect ability to become pregnant

---

*This comprehensive prescribing information incorporates the complete 2022 FDA labeling updates including detailed incidence rates, comprehensive adverse reaction profiles, postmarketing safety data, and enhanced safety monitoring protocols essential for GBM clinical practice.*